Vaccination Coverage and Level of Protection in Patients at Risk
Study of the Vaccination Coverage and Level of Protection Against Vaccine-preventable Infectious Diseases in Pediatric and Adult Risk Patients in a University Hospital
The purpose of this study is to determine
- vaccination coverage of recommended vaccines (routine childhood vaccines and vaccines against seasonal flu and pneumococci) in children with chronic diseases (allergy, cystic fibrosis, diabetes mellitus type 1, congenital heart disease, immunocompromised and solid organ transplant patients)
- the level of protection against measles, mumps, rubella and pertussis in children with chronic diseases.
- vaccination coverage of recommended vaccines (diphtheria, tetanus, pertussis and vaccines against seasonal flu and pneumococci) in adults with chronic diseases (nephropathy, diabetes mellitus, COPD, heart failure, HIV and solid organ transplant patients)
- the level of protection against diphtheria, tetanus and pertussis in adults with chronic diseases.
Studienübersicht
Status
Detaillierte Beschreibung
Chronically ill children
1.1 What is the vaccination status for vaccines recommended by the Superior Health Council in pediatric chronically ill patients (2-16 years of age) who consult within the University hospital of Leuven?
Patients with one of the following chronic conditions will be included:
- Cystic fibrosis
- Diabetes Mellitus type 1
- Allergic constitution
- Congenital heart disease
- Solid-organ transplantpatients
- Immunodeficiency (congenital or acquired)
- Cancer
The vaccination coverage for the following vaccines will be determined:
- Poliomyelitis
- Diphtheria
- Tetanus
- Pertussis
- Haemophilus influenzae type b
- Hepatitis B
- Measles-Mumps-Rubella
- Pneumococci
- Meningococcal serogroup C
- Rotavirus
- Diphtheria-Tetanus-Polio: booster (older than 7 years)
- Human papillomavirus (girls of 13 yrs)
- Seasonal flu (cystic fibrosis, immunodeficiencies)
Timeliness of the vaccines given will also be determined.
1.2 Is the vaccination coverage of pediatric patients (2-16 years of age) comparable to the data on healthy children in 2012?
1.3 What are possible factors that influence coverage in this specific patient populations?
1.4 If the vaccination coverage is too low (below 90-95 percent), what are possbile solutions to increase the coverage rates within this group?
1.5. Determine antibody titers in this same population for the following vaccine-preventable infectious diseases:
- Measles
- Mumps
- Rubella
- Pertussis
1.6 Are antibody titers in this population similar to antibody titers measured in seroprevalence studies of healthy children in the same age group?
- Adult patients at risk
2.1 What is the vaccinatiestatus for vaccines recommended by the Superior Health Council of adult patients at risk (over 18 years of age) who consult within the University hospital of Leuven?
Patients with one or more of the following chronic conditions will be included in the study:
- Chronic obstructive pulmonary disease (COPD)
- Heart failure
- Diabetes mellitus (Type 1 and 2)
- Chronic kidney disease (stadium IV and V)
- Solid organ Transplant patients
- HIV
- HSCT
The vaccination coverage for the following vaccines will be determined:
- Seasonal flu (yearly)
- Diphtheria-tetanus (date of last dose)
- Pneumococcus (1 dose/last dose before 5 years of age)
- Pertussis (1 dose)
- Hepatitis B (3 doses in specific risk groups)
2.2 Who immunizes these adult patients at risk?
2.3 What are possible risk factors who influences vaccination status in the adult population?
2.4 If the vaccination coverage is too low (below 90-95 percent), what are possible solutions to improve this coverage in these groups?
2.5 What are the antibody titers measured in the adult risk groups with a chronic condition for the following vaccine-preventable infectious diseases:
- Diphtheria
- Tetanus
- Pertussis
2.6 Are antibody titers measured in this population comparable to those of healthy subjects as measured in previous seroprevalence studies?
Studientyp
Einschreibung (Tatsächlich)
Kontakte und Standorte
Studienorte
-
-
-
Leuven, Belgien, 3000
- UZ Leuven
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Beschreibung
Inclusion Criteria:
- pediatric patients: be at least 2 years of age and maximum 16 ye
- adults patients: at least 18 years of age
- have a chronic condition
Exclusion Criteria:
-
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Beobachtungsmodelle: Kohorte
- Zeitperspektiven: Retrospektive
Kohorten und Interventionen
Gruppe / Kohorte |
|---|
|
Pediatric chronically ill patients
Through a questionnaire parents of chronically ill patients will be asked about the vaccination status of all recommended vaccines of their child. Also questions on disease, therapy and sociodemographic factors that can influence vaccination coverage will be asked. A blood sample to determine antibodies against measles, mumps, rubella and pertussis will be drawn from children who consent to sampling. The following groups of patients will be questioned: diabetes, allergy, congenital heart disease, cystic fibrosis, immunodeficiency and transplant patients, cancer patients. |
|
Adult chronically ill patients
Through a questionnaire chronically ill patients will be asked about their vaccination status of diphtheria, tetanus,pertussis, flu, pneumococcal and hepatitis B vaccine(s). Also questions on disease, therapy and sociodemographic factors that can influence vaccination coverage will be asked. A blood sample to determine antibodies against diphtheria, tetanus and pertussis will be drawn. The following groups of patients will be questioned: diabetes, chronic kidney disease, heart failure, COPD, immunodeficiency and transplant patients, HSCT patients. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Proportion of pediatric chronically ill patients correctly vaccinated with the hexavalent (DTaP-IPV-Hib-HBV), pneumococcal, rotavirus, MMR and MenC vaccine according to the Belgian recommended vaccination schedule.
Zeitfenster: 5 years
|
number of patients vaccinated compared to the entire group
|
5 years
|
|
Proportion of adult chronically ill patients correctly vaccinated diphtheria, tetanus, pneumococci, hepatitis B and influenza according to Belgian recommended vaccination schedule
Zeitfenster: 5 years
|
number of patients vaccinated compared to the entire group
|
5 years
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Proportion of pediatric patients with antibodies against measles, mumps, rubella, diphtheria, tetanus and pertussis in children included in the study and who provided a blood sample
Zeitfenster: 5 years
|
Determination of antibodies against measles, mumps, rubella and pertussis
|
5 years
|
|
Proportion of adult patients with antibodies against diphtheria, tetanus and pertussis.
Zeitfenster: 5 years
|
Determination of antibodies against diphtheria, tetanus and pertussis
|
5 years
|
Mitarbeiter und Ermittler
Ermittler
- Hauptermittler: Corinne Vandermeulen, MD, PhD, KU Leuven
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Erkrankungen des Verdauungssystems
- Herz-Kreislauf-Erkrankungen
- Erkrankungen der Atemwege
- Lungenkrankheit
- Urologische Erkrankungen
- Säugling, Neugeborenes, Krankheiten
- Niereninsuffizienz
- Genetische Krankheiten, angeboren
- Erkrankungen der Bauchspeicheldrüse
- Herzkrankheiten
- Nierenerkrankungen
- Niereninsuffizienz, chronisch
- Mukoviszidose
Andere Studien-ID-Nummern
- UZVACC
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .